4.8 Article

The NOTCH1/CD44 axis drives pathogenesis in a T cell acute lymphoblastic leukemia model

Journal

JOURNAL OF CLINICAL INVESTIGATION
Volume 128, Issue 7, Pages 2802-2818

Publisher

AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI92981

Keywords

-

Funding

  1. Ministerio de Economia y Competitividad (MINECO) [PLE-2009-0110, SAF2010-15106, SAF2013-44857-R, SAF2016-75442-R]
  2. Fundacion Sandra Ibarra
  3. Fundacion Asociacion Espanola Contra el Cancer [AECC CI13131229]
  4. Instituto de Salud Carlos III [RTICC RD06/0014/1012]
  5. European Union [602587]
  6. Fundacion Ramon Areces
  7. Banco de Santander
  8. MINECO

Ask authors/readers for more resources

NOTCH1 is a prevalent signaling pathway in T cell acute lymphoblastic leukemia (T-ALL), but crucial NOTCH1 downstream signals and target genes contributing to T-ALL pathogenesis cannot be retrospectively analyzed in patients and thus remain ill defined. This information is clinically relevant, as initiating lesions that lead to cell transformation and leukemia-initiating cell (LIC) activity are promising therapeutic targets against the major hurdle of T-ALL relapse. Here, we describe the generation in vivo of a human T cell leukemia that recapitulates T-ALL in patients, which arises de novo in immunodeficient mice reconstituted with human hematopoietic progenitors ectopically expressing active NOTCH1. This T-ALL model allowed us to identify CD44 as a direct NOTCH1 transcriptional target and to recognize CD44 overexpression as an early hallmark of preleukemic cells that engraft the BM and finally develop a clonal transplantable T-ALL that infiltrates lymphoid organs and brain. Notably, CD44 is shown to support crucial BM niche interactions necessary for LIC activity of human T-ALL xenografts and disease progression, highlighting the importance of the NOTCH1/CD44 axis in T-ALL pathogenesis. The observed therapeutic benefit of anti-CD44 antibody administration in xenotransplanted mice holds great promise for therapeutic purposes against T-ALL relapse.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available